Frontotemporal dementias (FTD) are the second most common type of presenile dementias, considered to be clinically and pathologically different from Alzheimer's dementia (AD). FTD differs clinically from AD because memory loss is rarely an early symptom. Instead, FTD is usually denoted by behavioural and language diffi culties, and may co-occur with motor neuron disease (MND). Frontotemporal lobar degeneration (FTLD) with ubiquitin-positive, tau-negative inclusions (FTLD-U) is the most common underlying pathology with and without MND. TAR DNA-binding protein 43 (TDP-43), encoded by the TARDBP gene, has been identifi ed as the major pathological protein of FTLD-U with or without MND, demonstrating that abnormal TDP-43 alone is suffi cient to cause neurodegeneration. FTLD is a genetically complex disorder. A proportion of cases of FTLD-U have various pathogenic mutations in the progranulin (GRN) gene. Other FTLD-U entities with TDP-43 proteinopathy include FTLD-U with valosin-containing protein (VCP) gene mutation and FTLD with MND linked to chromosome 9p. In contrast, chromosome 3-linked dementia, a FTLD-U with chromatic modifying protein 2B (CHMP2B) mutation, has TDP-43 negative inclusions. Thus, TDP-43 defi nes a novel class of neurodegenerative diseases called TDP-43 proteinopathies. These recent discoveries will contribute to an accurate diagnosis, and facilitate the development of diagnosis and therapy.
Frontotemporal dementias (FTD) are a clinically, genetically, and neuropathologically heterogeneous group of diseases accounting for up to 20 % of presenile dementia cases. FTD is a focal, non-Alzheimer form of dementia, clinically characterised as behavioural and/or language dysfunction, and may co-occur with motor neuron disease (MND) (1) . Typically, the patient with FTD does not have an amnestic syndrome, at least in the early stage of the disease, which distinguishes FTD clinically from Alzheimer's disease (AD) (2, 3) , but there are exceptions (4) . However, the clinical diagnosis of FTD may only be considered after other potential causes of dementia (e.g. small and/or large vessel disease), systemic conditions (e.g., hypothyroidism, vitamin B defi ciency), tumours, and substance abuse have been excluded. Frontotemporal lobar degeneration (FTLD) with ubiquitin-positive, tau-negative inclusions (FTLD-U or FTLD-MNDtype) is the most common underlying pathology in FTD with and without MND (5). TAR DNA-binding protein 43 (TDP-43), a nuclear protein implicated in exon skipping and transcription regulation (6, 7, 8) was recently identifi ed as the major pathological protein of sporadic and familial FTLD-U, with and without MND, as well as in sporadic amyotrophic lateral sclerosis (ALS), (9, 10) , and rapidly confi rmed by others (11, 12) . Pathologic TDP-43 in these disorders is abnormally phosphorylated, ubiquitinated and cleaved to generate C-terminal fragments, and is recovered only from pathologically affected CNS regions including hippocampus, neocortex, and spinal cord (10) . Therefore, the presence of abnormal aggregates of phoshorylated and ubiquitinated TDP-43 defi nes a novel class of neurodegenerative diseases called TDP-43 proteinopathies that includes FTLD-U, FTLD, MND, and ALS. The increasing life expectancy will result in increased prevalence of neurodegenerative diseases. This review focuses on exciting fi ndings providing a number of important advances in our understanding of the neuropathology, molecular genetics, and biochemistry of FTD, as one of neurodegenerative diseases that have occurred recently in this rapidly developing fi eld of dementia research.
NEUROPATHOLOGY OF FTLD
FTLD comprises a neuropathologically heterogeneous group of neurodegenerative diseases which share the common feature of predominant degeneration of the frontal and temporal lobes (13) (14) (15) . FTLD can broadly be divided into two main classes, based on abnormal accumulation of hyperphosphorylated tau protein: those with taupositive and with tau-negative inclusions. Whereas, in the past, most attention focused on FTLD associated with tau-based pathology and microtubule-associated protein tau gene (MAPT) mutations (tauopathies), there has recently been greater attention paid to nontau or tau-negative FTLD (non-tauopathies) (14) . FTLD-U accounts for 5 % to 15 % of all dementia disorders (16) .
GENETIC STUDIES
FTLD is a genetically complex disorder, with multiple genetic factors contributing to the disease. A positive family history with an autosomal dominant pattern of inheritance and high penetrance is usually found in one quarter to one half of patients (17, 18) . (14, 15) 
CLINICAL PHENOTYPE OF FTD
Recently, we retrospectively examined charts of 48 FTD individuals in order to find clinical differences between FTD and AD. All cases of FTD met pathological criteria for FTLD (14, 15) . Clinically, behavioural and language features, including impulsivity, disinhibition, and social withdrawal were signifi cantly different between FTD and AD, as reported previously (24) . The most distinctive feature of FTD, on psychometric tests, was a signifi cant impairment of frontal lobe functioning, as reported earlier (25) . The identifi cation of different mutations in the GRN gene in hereditary dysphasic disinhibition dementia families 1 and 2 (HDDD 1 and HDDD 2) (26, 27) links these families to other FTLD-U families with GRN mutation (28, 29) . A complicating feature in both HDDD families is the presence of AD-type early memory loss which correlated with coexisting AD pathology in almost half of the cases, which distinguishes them from other families with no or little coexisting neurodegenerative disease (26, 27) .
Interestingly, another family with the same GRN A9D mutation has been reported in an individual with corticobasal syndrome (30) , indicating, again, clinical heterogeneity associated with the same mutation.
CONCLUSION
For practicing clinicians, the knowledge that changes in behaviour and language difficulties distinguish those with FTD from AD is important, although clinical and cognitive features may overlap between the two. Typically, patients with FTD do not have an amnestic syndrome, at least in the early stage of the disease, which distinguishes them from AD.
Major discoveries have been made in the recent past in the genetics, biochemistry, and neuropathology of FTD. TDP-43, encoded by the TARDBP gene, is the major pathological protein of FTLD-U with or without MND. Thus, TDP-43 defines a novel class of neurodegenerative diseases called TDP-43 proteinopathies. FTLD-U is now recognised as the most common pathology associated with clinical FTLD. New developments such as the discovery of TDP-43 as disease protein have opened new view on FTD, as well as its relation to motor neuron disease.
In summary, the new genetic and pathological information now opens the way for a novel diagnostic approach. The diagnostic responsibility will increase with the development of new diagnostic tests. It is anticipated that these discoveries will contribute to an accurate diagnosis, and facilitate the development of specifi c therapy.
